



Business, Strategy and Portfolio Update

For the year ended 31 December 2023, and the period to date

Dr Ilian Iliev, CEO

19 March 2024

Disclaimer



This presentation (and any information contained in any oral presentation accompanying it) (**Presentation**) has been prepared by NetScientific Plc (**Company**). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (FSMA). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as **Information**) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a **Restricted Territory**), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.


Presentation

- Introduction to NetScientific (NSCI)
- Highlights of 2023
- Portfolio Highlights
- Outlook: Strategy Update
- Summary and Q&A



NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

- Identifying, investing in, and building high growth companies in the UK and internationally
- Proactive commercial management of portfolio
- Direct equity stakes in portfolio
- Selective balance sheet investments alongside EMV Capital (VC and corporate finance subsidiary) syndicated investments



Advantages of Model

- **Capital Efficient Investment Strategy:** supporting portfolio companies with selective use of balance sheet
- **Proactive Portfolio Management:** opens up value opportunities, investment on advantageous conditions
- **Value Creation Services:** selective support to portfolio companies – accelerating growth and de-risking
- **Fee-Based Services:** offsetting running costs
- **Internationalisation:** footprint and network in US and EU – helping companies internationalise early
- **Portfolio Synergies:** accelerating growth and creating new opportunities for innovation



Effective Board Leadership & Corporate Governance



Dr. Ilian Iliev, CEO

- Founder of EMV Capital – acquired by NetScientific PLC in 2020
- Significant shareholder of NetScientific (15%+)
- Experienced investor, negotiator, strategist & hands-on manager
- IP commercialisation at CambridgeIP; experience in energy, industrials, medtech
- PhD Cambridge University Judge Business School



Ed Hooper, Executive Director and Group General Counsel

- Former Partner of a City headquartered international law firm
- 20+ years' experience as a lawyer, specialising in advising on a broad range of transactions, including fundraisings, M&A, IPOs, joint ventures and restructurings, many on an international scale
- Solicitor of the Senior Courts of England and Wales



Dr. Charles Spicer, Non-Executive Chair

- Experienced chair and director in the medtech and life sciences industries
- Previously head of healthcare at Nomura, Numis
- Ex-Chief Executive of MDY Healthcare plc, a healthcare investor
- PhD in History from London University; MA Cambridge University



Dr. Jonathan Robinson, Non-Executive Director

- Experienced company director, entrepreneur and investor
- Co-founded the publicly quoted Group NBT plc, which ultimately became NetNames Group. Director and CEO of the group
- Previously non-executive director of Nominet
- PhD in Materials Engineering from University of Cape Town



Stephen Crowe, CFO

- Experienced finance leader with 25+ years' experience in a wide range of financial institutions from blue chip organisations (AXA) to SMEs (THB Group, R K Carvill & Co. and Towergate Partnership)
- Qualified chartered accountant
- Degree from Auckland University (NZ)

SUPPORTED BY STRONG OPERATIONAL AND INVESTMENT TEAM, VENTURE PARTNERS AND ADVISERS

Group Portfolio – Diversified Risk and Increased Investment Return Opportunities



23 companies in Life Sciences, Deeptech and Sustainability segments



**Portfolio comprises of equity investments and exposure to companies through carried interest, realisable on exit*


BALANCED PORTFOLIO FOR ENHANCED PERFORMANCE AND RISK MITIGATION

- **Modest increase expected in Fair Value** of the privately held assets as at 31 December 2023
- Across the Group's portfolio of 23 companies, an **aggregate amount of c.£52.2 million raised** through equity and venture debt by 13 companies
- **Significant increase in Capital Under Advisory** by £6.6 million
- A **proprietary trade profit of £0.5 million** in respect of the secondary sales of a £1.4 million position across two portfolio companies
- **Increase in fees generated by EMV Capital**, covering approximately half of the core Group's costs, whilst providing infrastructure and services to the Group
- EMV Capital received **direct FCA authorisation**, enabling it to expand and deepen its corporate finance and fund management activities

SIGNIFICANT PROGRESS IN CHALLENGING MARKET CONDITIONS

CONTINUED SUPPORT THROUGH SUCCESSIVE STAGES

- Concentrating on a “cohort” of companies, taking deeper stakes, with a focus on value creation and investment realisations
- Selective new investments that align with our model, offer good value, and can benefit from value creation services



Selected Portfolio Company Highlights



ProAxis Ltd, UK (medtech, respiratory diagnostics, 81.9% direct, 8.7% CUA)

- Strengthened Board with appointment of Alan Markey as Chair and Professor Steven Myint as Non-Executive Director
- Intensifying the development of its Patient Point of Care product range
- Has appointed EMV Capital and an external adviser to explore options for a potential sale of the company
- Seeking a new strategic owner better placed to provide the funding, resourcing and infrastructure to scale the business to its full potential
- EMV Capital continues its mandate to procure further third-party funding for the company




Glycotest, Inc., US (liver cancer diagnostics, 52.7% direct, 5.8% CUA)

- Secured \$1m investment from Fosun, alongside private investment of c.\$800,000 syndicated by EMV Capital
- Completed enrolment in a clinical validation study for its HCC Panel
- Positioned to move through sample assay and data analysis to demonstrate superiority of the Glycotest HCC Panel relative to AFP Tumour Market Test



PDS Biotechnology Corp, NASDAQ: PDSB (Immuno-oncology, 3.5% direct)

- Made substantial clinical progress across its pipeline of targeted cancer immunotherapies
- Announced 75% of ICI-naïve patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients
- Also announced two-year overall survival rate of 74% in Phase 2 trial of ICI-naïve HPV16-positive recurrent or metastatic head and neck cancer patients
- Current market cap c.\$147m (14 March 24)



TARGETED COMPANIES WITH POTENTIAL FOR GREATER RETURNS

Selected Portfolio Company Highlights



Q-Bot, UK (robotics as a service, home retrofit insulation, 14.3% direct, 32.4% CUA)

- EMV Capital lead a £3.5m fundraising for expansion in the UK, Europe, and the USA
- Strengthened its Board with a proposed new Chair (in advance stages) and Malcolm Groat as Investment Director
- Achieved 10,000 property surveys and around 4,500 installations
- Won contracts in the Registered Social Housing sector
- Commenced expansion into the Netherlands, exploring Belgium as a next market





Sofant Technologies, UK (semiconductors satellite comms, 1.4% direct, 25% CUA)

- Made significant progress on product commercialisation, targeting product launch in 2024
- Advance orders with Inmarsat (now part of Viasat), with the European Space Agency and a global aerospace company
- Claims up to 70% energy efficiency advantage and cost savings due to modular design
- Previously completed a £1.2m investment round, led by EMV Capital



Vortex, US-UK (liquid biopsy, oncology, 22.1% direct, 15.4% CUA)

- EMV Capital led and syndicated a £3.2m fundraise
- Expanded its lab facilities at the London Cancer Hub's Innovation Gateway
- Focused on generating studies with leading researchers including Imperial College London and University of Cambridge to highlight evidence of the technology
- Appointed Paul Reeves as Chief Technology Officer



TARGETED COMPANIES WITH POTENTIAL FOR GREATER RETURNS

Selected Portfolio Company Highlights



Ventive Limited, UK (heat pumps and passive air ventilation, 10.9% direct, 24.9% CUA)

- Secured c.£900,000 investment led by EMV Capital, non-dilutive funding from the £1.5m DESNZ grant, and a £100,000 UK Government grant for 'net zero HVAC' systems
- Scaling its team with strategic senior hires
- Completing the design, test phase and factory build for its modular heat pumps
- Undergoing further enhancements to its passive air ventilation product range




Deeptech Recycling Limited, UK (recycling, 30% direct)

- Secured a first investment of £1m in ASA funding, led by EMV Capital
- Commercialising its patented technology and developing commercial opportunities focused on scalable chemical recycling technology
- Progressing its commercial operations with a transition into new premises and key strategic hires



Martlet Capital, UK (early-stage deep tech and life sciences investor, 1% direct, 5.9% CUA)

- Our strategic investment in Martlet Capital was focused on obtaining options on investments coming from the Cambridge high-tech cluster
- Martlet continued to grow its investment portfolio, including participation in funding rounds for Nu Quantum, Spotta, OctaiPipe and Xampla
- EMV Capital working closely with Martlet Capital to deepen the relationship between the two firms, expected to result in future projects and co-investments



TARGETED COMPANIES WITH POTENTIAL FOR GREATER RETURNS

Outlook: Strategy Update



Grow the value of the NSCI stakes in portfolio companies:



- Capital efficient investment in core companies
- Active management
- Provision of Value Creation Services

Progress fund management practice:

- Annual recurring revenue (management fees)
- Carried interest potential
- Potential liquidity events and scaled funding capacity

Create effective routes to exit for portfolio companies:

- Increased balance sheet strength, allowing to pursue 'evergreen' investment strategy
- Exit strategies being mapped for several portfolio companies



Outlook: Strategy Update





Build a resilient, high-performance firm:

- Developing team and operating platform
- Scaling investment and fund management opportunities

Achieve financial sustainability:

- Moving to cover core operating costs through
 - **operational income** (corporate finance fees, value creation services fees, and fund management fees) and
 - **secondary trading income** (through the profitable exits of full or partial holdings in portfolio companies)



Advancing a Robust and Sustainable Business Model

- Positioned to take advantage of the VC industry shift
- Exploring opportunities to take on the management of two existing funds
- Exit strategies being mapped for several portfolio companies
- Align underlying asset value with market cap

Thank you! Q&A

www.netscientific.net